secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch Health Companies Inc. (BHC)
CIK:        0000885590
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001193125-23-247446
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 9.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Bausch + Lomb completes $2.5B XIIDRA acquisition from Novartis, funded with $1.9B debt
--------------------------------------------------------------------------------

- Upfront $1.75B cash plus up to $750M milestone for XIIDRA and other ophthalmology assets from Novartis.
- Funded by $1.4B 8.375% senior secured notes due 2028 and $500M term B loans.
- Notes mature Oct 1, 2028; interest payable semi-annual; secured by first-priority liens.
- Bausch + Lomb also acquired the sales force supporting XIIDRA.
- Closing occurred September 29, 2023, consistent with prior announcements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885590/000119312523247446/0001193125-23-247446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885590/000119312523247446/d490226d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-247446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer